Barbara D. Lovász

1.8k total citations
46 papers, 890 citations indexed

About

Barbara D. Lovász is a scholar working on Genetics, Epidemiology and Surgery. According to data from OpenAlex, Barbara D. Lovász has authored 46 papers receiving a total of 890 indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Genetics, 29 papers in Epidemiology and 19 papers in Surgery. Recurrent topics in Barbara D. Lovász's work include Inflammatory Bowel Disease (33 papers), Microscopic Colitis (29 papers) and Eosinophilic Esophagitis (7 papers). Barbara D. Lovász is often cited by papers focused on Inflammatory Bowel Disease (33 papers), Microscopic Colitis (29 papers) and Eosinophilic Esophagitis (7 papers). Barbara D. Lovász collaborates with scholars based in Hungary, Canada and United States. Barbara D. Lovász's co-authors include Péter L. Lakatos, Petra A. Golovics, Zsuzsanna Végh, Lajos S. Kiss, Tünde Pandúr, Mihály Balogh, Zsuzsanna Kürti, Miklós Szathmári, Zsuzsanna Erdélyi and Gyula Dávid and has published in prestigious journals such as Gastroenterology, The American Journal of Gastroenterology and World Journal of Gastroenterology.

In The Last Decade

Barbara D. Lovász

44 papers receiving 874 citations

Peers

Countries citing papers authored by Barbara D. Lovász

Since Specialization

Citations

This map shows the geographic impact of Barbara D. Lovász's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barbara D. Lovász with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barbara D. Lovász more than expected).

Fields of papers citing papers by Barbara D. Lovász

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Barbara D. Lovász. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barbara D. Lovász. The network helps show where Barbara D. Lovász may publish in the future.

Co-authorship network of co-authors of Barbara D. Lovász

This figure shows the co-authorship network connecting the top 25 collaborators of Barbara D. Lovász. A scholar is included among the top collaborators of Barbara D. Lovász based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Barbara D. Lovász. Barbara D. Lovász is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Comparison of Efficacy and Safety of Commercially Available Fixed-Ratio Combinations of Insulin Degludec/Liraglutide and Insulin Glargine/Lixisenatide: A Network Meta-analysis 2023 ·Canadian Journal of Diabetes ·(unknown), (unknown), (unknown), Anna Péterfi, Barbara D. Lovász, Szilvia Mészáros, Viktor J. Horváth, Ádám G. Tabák	9
2	First prospective European study for the feasibility and safety of magnetically controlled capsule endoscopy in gastric mucosal abnormalities 2022 ·World Journal of Gastroenterology ·M Szalai, (unknown), Barbara D. Lovász, (unknown), A Rosztóczy, (unknown), L Madácsy	7
3	Network meta-analysis of prophylactic pancreatic stents and non-steroidal anti-inflammatory drugs in the prevention of moderate-to-severe post-ERCP pancreatitis 2021 ·Pancreatology ·Zsolt Dubravcsik, István Hritz, (unknown), Péter Novák, Barbara D. Lovász, L Madácsy	15
4	Therapeutic preferences and outcomes in newly diagnosed patients with Crohn’s diseases in the biological era in Hungary: a nationwide study based on the National Health Insurance Fund database 2018 ·BMC Gastroenterology ·Zsuzsanna Kürti, Ákos Iliás, Lóránt Gönczi, Zsuzsanna Végh, (unknown), (unknown), Petra A. Golovics, Barbara D. Lovász, Péter L. Lakatos	4
5	Quality of care indicators in inflammatory bowel disease in a tertiary referral center with open access and objective assessment policies 2017 ·Digestive and Liver Disease ·Lóránt Gönczi, Zsuzsanna Kürti, Petra A. Golovics, Barbara D. Lovász, (unknown), (unknown), (unknown), (unknown), Ákos Iliás, (unknown), K Gecse, (unknown), Waqqas Afif, Alain Bitton, Zsuzsanna Végh, Péter L. Lakatos	10
6	Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseases 2017 ·BMC Gastroenterology ·Lóránt Gönczi, Zsuzsanna Kürti, Mariann Rutka, Zsuzsanna Végh, Klaudia Farkas, Barbara D. Lovász, Petra A. Golovics, K Gecse, Balázs Szalay, Tamás Molnár, Péter L. Lakatos	18
7	Perceived Risks Contra Benefits of Using Biosimilar Drugs in Ulcerative Colitis: Discrete Choice Experiment among Gastroenterologists 2016 ·Value in Health Regional Issues ·Petra Baji, László Gulàcsi, Petra A. Golovics, Barbara D. Lovász, Márta Péntek, Valentin Brodszky, Fanni Rencz, Péter L. Lakatos	10
8	Nationwide prevalence and drug treatment practices of inflammatory bowel diseases in Hungary: A population-based study based on the National Health Insurance Fund database 2016 ·Digestive and Liver Disease ·Zsuzsanna Kürti, Zsuzsanna Végh, Petra A. Golovics, (unknown), K Gecse, Lóránt Gönczi, (unknown), Barbara D. Lovász, Péter L. Lakatos	26
9	P295. Preliminary assessment of efficacy and safety of switching between originator and biosimilar infliximab in paediatric Crohn disease patients. 2015 ·Journal of Crohn s and Colitis ·Zsuzsanna Kürti, K Gecse, Anita Bálint, Klaudia Farkas, Barbara D. Lovász, András Szabó, M. Mandel, (unknown), Koloman Krištof, Zsuzsanna Végh, (unknown), Tamás Molnár, László Kiss, Petra A. Golovics, Péter L. Lakatos	2
10	Does Hospitalization Predict the Disease Course in Ulcerative Colitis? Prevalence and Predictors of Hospitalization and Re- Hospitalization in Ulcerative Colitis in a Population-based Inception Cohort (2000-2012) 2015 ·Journal of Gastrointestinal and Liver Diseases ·Petra A. Golovics, Péter L. Lakatos, (unknown), Barbara D. Lovász, Zsuzsanna Végh, Zsuzsanna Kürti, (unknown), Lajos S. Kiss, Mihály Balogh, Tünde Pandúr	16
11	Risk Matrix for Prediction of Disease Progression in a Referral Cohort of Patients with Crohn’s Disease 2015 ·Journal of Crohn s and Colitis ·Péter L. Lakatos, Nóra Sipeki, György Kovács, (unknown), Gary L. Norman, Zakera Shums, Petra A. Golovics, Barbara D. Lovász, Péter Antal‐Szalmás, Mária Papp	10
12	Tuberculin Skin Test and Quantiferon in BCG Vaccinated, Immunosuppressed Patients with Moderate-to-Severe Inflammatory Bowel Disease 2015 ·Journal of Gastrointestinal and Liver Diseases ·Zsuzsanna Kürti, Barbara D. Lovász, K Gecse, Anita Bálint, Klaudia Farkas, (unknown), (unknown), Koloman Krištof, Zsuzsanna Végh, Lóránt Gönczi, Lajos S. Kiss, Petra A. Golovics, L. Lakatos, Tamás Molnár, Péter L. Lakatos	13
13	Incidence rates and disease course of paediatric inflammatory bowel diseases in Western Hungary between 1977 and 2011 2014 ·Digestive and Liver Disease ·Barbara D. Lovász, Péter L. Lakatos, Ágnes Horváth, Tünde Pandúr, Zsuzsanna Erdélyi, Mihály Balogh, István Szipócs, Zsuzsanna Végh, Gábor Veres, Katalin Eszter Müller, Petra A. Golovics, Lajos S. Kiss, (unknown)	30
14	Decreasing trends in hospitalizations during anti-TNF therapy are associated with time to anti-TNF therapy: Results from two referral centres 2014 ·Digestive and Liver Disease ·(unknown), Anita Bálint, Petra A. Golovics, Zsuzsanna Végh, (unknown), (unknown), (unknown), Zsuzsanna Kürti, Lajos S. Kiss, Barbara D. Lovász, K Gecse, Klaudia Farkas, Tamás Molnár, Péter L. Lakatos	26
15	Low incidence of venous thromboembolism in inflammatory bowel diseases: prevalence and predictors from a population-based inception cohort 2014 ·Scandinavian Journal of Gastroenterology ·Zsuzsanna Végh, Petra A. Golovics, Barbara D. Lovász, Zsuzsanna Kürti, K Gecse, (unknown), Mihály Balogh, Tünde Pandúr, Péter L. Lakatos	15
16	Is Current Smoking Still an Important Environmental Factor in Inflammatory Bowel Diseases? Results from a Population-based Incident Cohort 2013 ·Inflammatory Bowel Diseases ·Péter L. Lakatos, Zsuzsanna Végh, Barbara D. Lovász, Gyula Dávid, Tünde Pandúr, Zsuzsanna Erdélyi, (unknown), Gábor Mester, Mihály Balogh, István Szipócs, Csaba Molnár, Erzsébet Komáromi, Petra A. Golovics, M. Mandel, Ágnes Horváth, Miklós Szathmári, Lajos S. Kiss	79
17	Evolution of disease phenotype in adult and pediatric onset Crohn’s disease in a population-based cohort 2013 ·World Journal of Gastroenterology ·Barbara D. Lovász	51
18	New trends in inflammatory bowel disease epidemiology and disease course in Eastern Europe 2012 ·Digestive and Liver Disease ·Barbara D. Lovász, Petra A. Golovics, Zsuzsanna Végh, Péter L. Lakatos	43
19	The risk of lymphoma and immunomodulators in patients with inflammatory bowel diseases: Results from a population-based cohort in Eastern Europe 2012 ·Journal of Crohn s and Colitis ·Péter L. Lakatos, Barbara D. Lovász, Gyula Dávid, Tünde Pandúr, Zsuzsanna Erdélyi, Gábor Mester, Mihály Balogh, István Szipócs, Csaba Molnár, Erzsébet Komáromi, Petra A. Golovics, Zsuzsanna Végh, M. Mandel, Ágnes Horváth, Miklós Szathmári, Lajos S. Kiss	24
20	High-sensitivity C-reactive protein for identification of disease phenotype, active disease, and clinical relapses in Crohnʼs disease: A marker for patient classification? 2011 ·Inflammatory Bowel Diseases ·Lajos S. Kiss, Mária Papp, Barbara D. Lovász, Zsuzsanna Végh, Petra A. Golovics, Eszter Anna Janka, E.‐M. Varga, Miklós Szathmári, Péter L. Lakatos	68

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact